Analysis of risk factors for arteriosclerosis renal artery stenosis

doi:10.3877/cma.j.issn.2095-8757.2020.02.009

Abstract

Abstract:

Objective

To investigate the risk factors of arteriosclerosis renal artery stenosis (ARAS) in aged patients.

Methods

140 elderly patients underwent renal artery color doppler ultrasound examination at First People's Hospital of Ningyang County from January 2016 to June 2019 were selected. The clinical data of ARAS patients and non-ARAS patients were compared. The indicators with statistically significant difference in univariate analysis (T test or chi-square test) were incorporated into Logistic regression model for multivariate analysis.

Results

Among the 140 patients, 68 patients were ARAS (ARAS group) and 72 patiens were non-ARAS (non-ARAS group). The age, the proportion of hypertension history and diabetes history, the levels of homocysteine (HCY) and hypersensitive C-reactive protein (hs-CRP) in the ARAS group were significantly higher than those in the non-ARAS Group (χ²=3.657, 3.897; t=-2.970, 3.989, -3.360; P < 0.05). Logistic regression analysis showed that age, hypertension history, HCY level and hs-CRP level were the independent risk factors [OR(95%CI)=1.077(1.019-1.138), 4.814(2.006-11.552), 1.072(1.026-1.119), 1.345(1.190-1.520), P < 0.01] in elderly patients with ARAS.

Conclusion

Early detection of high risk patients and targeted improvement of risk factors have important clinical significance for the treatment and prognosis of ARAS.

Key words: Arteriosclerosis, Renal artery stenosis, Risk factors, Ultrasound

Qiang Chen, Bingjie Zuo, Yan Liu, Lei Su, Guohua Sun. Analysis of risk factors for arteriosclerosis renal artery stenosis[J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2020, 07(02): 36-39.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlnbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8757.2020.02.009

https://zhlnbyjdzzz.cma-cmc.com.cn/EN/Y2020/V07/I02/36

Figures/Tables 2

References 27

[1]	Derkx FH, Schalekamp MA. Renal artery stenosis and hypertension[J]. Lancet, 1994, 344(8917):237-239.
[2]	Rimmer JM, Gennari FJ. Atherosclerotic renovascular disease and progressive renal failure[J]. Annal Int Med, 1993, 118(9):712.
[3]	Zierler RE, Bergelin RO, Isaacson JA, et al. Natural history of atherosclerotic renal artery stenosis: A prospective study with duplex ultrasonography[J]. J Vasc Surg, 1994, 19(2):250-258.
[4]	Crowley JJ, Santos RM, Peter RH, et al. Progression of renal artery stenosis in patients undergoing cardiac catheterization[J]. Am Heart J, 1998, 136(5):913-918.
[5]	Cheung CM, Hegarty J, Kalra PA. Dilemmas in the management of renal artery stenosis[J]. Br Med Bull, 2005, 73-74:35-55.
[6]	Hansen KJ, Edwards MS, Craven TE, et al. Prevalence of renovascular disease in the elderly: A population-based study[J]. J Vasc Surg, 2002, 36(3):443-451.
[7]	Hoyer-Kuhn H, Kohbrok S, Volland R, et al. Vitamin b6 in primary hyperoxaluria I: first prospective trial after 40 years of practice[J]. Clin J Am Soc Nephrol, 2014, 9(3):468-477.
[8]	Conlon PJ, Little MA, Pieper K, et al. Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography[J]. Kidney Int, 2001, 60(4):1490-1497.
[9]	Mcclellan WM, Newsome BB, Mcclure LA, et al. Chronic kidney disease is often unrecognized among patients with coronary heart disease: The REGARDS Cohort Study[J]. Am J Nephrol, 2008, 29(1):10-17.
[10]	Kalra PA, Guo H, Kausz AT, et al. Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis[J]. Kidney Int, 2005, 68(1):293-301.
[11]	Conlon PJ, Athirakul K, Kovalik E, et al. Survival in renal vascular disease[J]. J Am Soc Nephrol, 1998, 9(2):252-256.
[12]	Chábová V, Schirger A, Stanson AW, et al. Outcomes of atherosclerotic renal artery stenosis managed without revascularization[J]. Mayo Clin Proc, 2000, 75(5):437-444.
[13]	Herrmann SMS, Saad A, Textor SC, et al. Management of atherosclerotic renovascular disease after Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)[J]. Nephrology, 2014, 30(3):366-375.
[14]	Wang Y, Ho D, Chen WH, et al. Prevalence and predictors of renal artery stenosis in Chinese patients with coronary artery disease[J]. Int Med J, 2003, 33(7):280-285.
[15]	Hansen KJ, Edwards MS, Craven TE, et al. Prevalence of renovascular disease in the elderly: A population-based study[J]. J Vasc Surg, 2002, 36(3):443-451.
[16]	Olivieri O, Friso S, Trabetti E, et al. Homocysteine and atheromatous renal artery stenosis[J]. Clin Exp Med, 2001, 1(4):211-218.
[17]	Chen Z, Li J, Yang Y, et al. The renal artery is involved in Chinese arteritis patients[J]. Kidney Int, 2018, 93(1):30496-30499.
[18]	Chade AR, Rodriguez-Porcel M, Grande JP, et al. Distinct renal injury in early atherosclerosis and renovascular disease[J]. Circulation, 2002, 106(9):1165-1171.
[19]	Fananapazir G, McGahan JP, Corwin MT, et al. Screening for transplant renal artery stenosis: ultrasound -based stenosis probability stratification[J]. Am J Roentgenol, 2017, 209(5):1064-1073.
[20]	Lerman LO, Textor SC, Grande JP. Mechanisms of tissue injury in renal artery stenosis: Ischemia and beyond[J]. Prog Cardiovasc Dis, 2010, 52(3):196-203.
[21]	Vehkavaara S, Ykijärvinen H. 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes[J]. Arterioscler Thromb Vasc Biol, 2004, 24(2):325-330.
[22]	Kotliar C, Juncos L, Inserra F, et al. Local and systemic cellular immunity in early renal artery atherosclerosis[J]. Clin J Am Soc Nephrol, 2012, 7(2):224-230.
[23]	Sun D, Eirin A, Ebrahimi B, et al. Early atherosclerosis aggravates renal microvascular loss and fibrosis in swine renal artery stenosis[J]. J Am Soc Hypertens, 2016, 10(4):325-335.
[24]	Preston RA, Jy W, Jimenez JJ, et al. Effects of severe hypertension on endothelial and platelet microparticles[J]. Hypertension, 2003, 41(2):211-217.
[25]	Franck G, Mawson T, Sausen G, et al. Flow perturbation mediates neutrophil recruitment and potentiates endothelial injury via TLR2 in mice: Implications for superficial erosion[J]. Circul Res, 2017, 121(1):31-42.
[26]	Caniffi C, Cerniello FM, Bouchet G, et al. Chronic treatment with C-type natriuretic peptide impacts differently in the aorta of normotensive and hypertensive rats[J]. Pflügers Arch, 2019, 471(8):1103-1115.
[27]	Zhang Y, Ge JB, Qian JY. Prevalence and risk factors of atherosclerotic renal artery stenosis in 1,200 Chinese patients undergoing coronary angiography[J]. Nephron Clin Pract, 104(4):c185-c192.

组别	例数	年龄（岁）	性别（男/女，例）	病史[例(%)]			吸烟[例（%）]	饮酒[例（%）]
组别	例数	年龄（岁）	性别（男/女，例）	糖尿病	高血压	冠心病	吸烟[例（%）]	饮酒[例（%）]
ARAS组	68	78.0±5.4	38/30	38（55.9）	40（58.8）	36（52.9）	32（47.1）	27（39.7）
非ARAS组	72	68.7±5.6	37/35	32（44.4）	35（48.6）	34（47.2）	28（38.9）	28（38.9）
检验值	?	t=-2.970	χ²=0.924	χ²=3.657	χ²=3.897	χ²=0.485	χ²=0.241	χ²=0.113
P值	?	<0.01	>0.05	<0.05	<0.05	>0.05	>0.05	>0.05
组别	例数	LDL-C（mmol/L）	HDL-C（mmol/L）	HCY（mol/L）	hs-CRP（mg/L）	SBP（mmHg）	DBP（mmHg）
ARAS组	68	3.15±1.23	1.33±0.20	18.25±3.49	4.35±1.32	142.0±9.4	86.0±5.1
非ARAS组	72	3.16±1.21	1.32±0.30	13.87±2.68	2.29±1.56	129.0±8.5	78.0±6.3
检验值	?	t=-0.354	t=-0.311	t=3.989	t=-3.360	t=0.217	t=0.289
P值	?	>0.05	>0.05	<0.01	<0.01	>0.05	>0.05

组别	例数	年龄（岁）	性别（男/女，例）	病史[例(%)]			吸烟[例（%）]	饮酒[例（%）]
组别	例数	年龄（岁）	性别（男/女，例）	糖尿病	高血压	冠心病	吸烟[例（%）]	饮酒[例（%）]
ARAS组	68	78.0±5.4	38/30	38（55.9）	40（58.8）	36（52.9）	32（47.1）	27（39.7）
非ARAS组	72	68.7±5.6	37/35	32（44.4）	35（48.6）	34（47.2）	28（38.9）	28（38.9）
检验值	?	t=-2.970	χ²=0.924	χ²=3.657	χ²=3.897	χ²=0.485	χ²=0.241	χ²=0.113
P值	?	<0.01	>0.05	<0.05	<0.05	>0.05	>0.05	>0.05
组别	例数	LDL-C（mmol/L）	HDL-C（mmol/L）	HCY（mol/L）	hs-CRP（mg/L）	SBP（mmHg）	DBP（mmHg）
ARAS组	68	3.15±1.23	1.33±0.20	18.25±3.49	4.35±1.32	142.0±9.4	86.0±5.1
非ARAS组	72	3.16±1.21	1.32±0.30	13.87±2.68	2.29±1.56	129.0±8.5	78.0±6.3
检验值	?	t=-0.354	t=-0.311	t=3.989	t=-3.360	t=0.217	t=0.289
P值	?	>0.05	>0.05	<0.01	<0.01	>0.05	>0.05

指标	B	Wald	OR	95%CI	P值
年龄	0.074	6.969	1.077	1.019-1.138	<0.01
糖尿病病史	0.592	0.975	1.807	0.558-5.847	>0.05
高血压病史	1.571	12.379	4.814	2.006-11.552	<0.01
HCY	0.069	9.661	1.072	1.026-1.119	<0.01
hs-CRP	0.296	22.592	1.345	1.190-1.520	<0.01

指标	B	Wald	OR	95%CI	P值
年龄	0.074	6.969	1.077	1.019-1.138	<0.01
糖尿病病史	0.592	0.975	1.807	0.558-5.847	>0.05
高血压病史	1.571	12.379	4.814	2.006-11.552	<0.01
HCY	0.069	9.661	1.072	1.026-1.119	<0.01
hs-CRP	0.296	22.592	1.345	1.190-1.520	<0.01

Please choose a citation manager

Content to export